J Korean Cancer Assoc.
2000 Aug;32(4):750-756.
Cell Cylce Regulatory Effects of Cyclic AMP
in Cancer Cells Which Lack Wild-type p53
- Affiliations
-
- 1Department of Internal Medicine, Gyeongsang National University College of Medicine
and Gyeongsang Institute of Cancer Research, Chinju, Korea.
- 2Department of Pediatrics, 3Medicine Branch, National Cancer Institute,
National Institute of Health, Bethesda, MD, USA.
Abstract
-
PURPOSE: The activator of protein kinase A, cyclic AMP, has been a recognized growth inhibitor
of certain cell types. The present study aimed to investigate the effects of dibutyryl cAMP on
the growth of cancer cells which lack wild-type p53 and to determine the mechanism of growth
inhibition.
MATERIALS AND METHODS
Prostate and breast cancer cells were treated with dibutyryl cAMP and
compared with untreated cells. Growth patterns of cells were assessed by trypan blue-excluding
method and western blot was done to determine protein levels of cell cycle regulatory proteins
which govern G1 and G1/S phase. Northern blot and immunoprecipitation were done to determine
the level of mRNA of p21 and the association between cell cycle regulatory proteins. In vitro
immune complex kinase assay was done to assess the activity of cdk2.
RESULTS
cAMP reduced cell growth by 48 h. Cyclin D3 level was downregulated and RB protein
level was decreased and mostly unphosphorylated forms remained. The association of RB with
E2F1 was increased. While cdk2 levels remained constant throughout cAMP treatment, the
activity of cdk2/cyclin E complex, which is responsible for entry into S phase, was downregulated.
Cdk inhibitors, p27 and p21 were induced with cAMP treatment.
CONCLUSION
These observation suggest that the growth inhibitory effects of dibutyryl cAMP on
prostate and breast cancer cells were mediated by induction of cdk inhibitors such as p21 and
p27 and RB activation in accordance with downregulation of cdk2.